Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced its participation in the 18th Annual WORLD Symposium™ on lysosomal storage diseases, taking place from February 7-11, 2022, in San Diego, California.
The company will present updated data from the Phase 1/2 MARVEL-1 clinical trial for FLT190, targeting Fabry disease, and detail the GALILEO-1 design, assessing FLT201 for Gaucher disease Type 1.
Presentations will be delivered by Derralynn A. Hughes, with a platform presentation on February 11 and poster presentations on February 8 and 9.
- None.
- None.
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that it will deliver a platform presentation and two poster presentations at the 18th Annual WORLDSymposium™, a research conference dedicated to lysosomal storage diseases, taking place February 7 – 11, 2022 in San Diego, California. The presentations will include updated data from the Company’s ongoing Phase 1/2 MARVEL-1 clinical trial evaluating FLT190 for the treatment of patients with Fabry disease and the clinical trial design for GALILEO-1, a Phase 1/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1.
Platform Presentation Details:
| Title: | Safety and efficacy of FLT190 for the treatment of patients with Fabry disease: Results from the MARVEL-1 Phase 1/2 clinical trial |
| Presenter: | Derralynn A. Hughes |
| Session: | Late-Breaking Science |
| Date and Time: | Friday, February 11, 2022, 8:00 AM PT |
Poster Presentation Details:
| Title: | Safety and efficacy of FLT190 for the treatment of patients with Fabry disease: Results from the MARVEL-1 Phase 1/2 clinical trial |
| Authors: | Derralynn A. Hughes, Sima Canaan-Kühl, Sharon Barton, Richard Collis, Nicole Sherry |
| Presentation #: | LB-30 |
| Date: | Tuesday, February 8, 2022 |
| Title: | Design of GALILEO-1, a Phase 1/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease Type 1 |
| Authors: | Derralynn A. Hughes, Sharon Barton, Nicole Sherry |
| Presentation #: | 127 |
| Date: | Wednesday, February 9, 2022 |
The poster presentations will be available on the Investors section of Freeline’s website following presentation at the WORLDSymposium™ conference.
About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the US.
Forward-Looking Statements
This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. The Company cannot guarantee that any forward-looking statement will be realized. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated, or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2020 and in subsequent reports on Form 6-K, in each case including in the sections thereof captioned “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3.D. Risk factors.” Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the Company’s reports and documents filed with the U.S. Securities and Exchange Commission (the “SEC”). You may review these documents by visiting EDGAR on the SEC website at www.sec.gov.
Contact
David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947
FAQ
When will Freeline Therapeutics present at the WORLD Symposium 2022?
What studies will Freeline discuss at the WORLD Symposium?
Who is presenting on behalf of Freeline at the conference?
What is the significance of the MARVEL-1 and GALILEO-1 trials for Freeline Therapeutics?
Where can I find more information about the presentations from Freeline at the WORLD Symposium?
